Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523173 | 0.98 | MAPK14 (0.60) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL3523946 | 0.85 | MAPK14 (0.47) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL3525483 | 0.84 | MAPK14 (0.53) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL4220189 | 0.83 | MAPK14 (0.60) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL4217134 | 0.83 | MAPK14 (0.49) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL13546265 | 0.82 | MAPK14 (0.55) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL4225095 | 0.82 | MAPK13 (0.53) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL4230157 | 0.82 | MAPK14 (0.51) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL3524260 | 0.82 | MAPK13 (0.50) | MAPK14CYP2C9MAPK13ABL1 | |
| SCHEMBL4215052 | 0.81 | MAPK13 (0.55) | MAPK14CYP2C9MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | claimed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | claimed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | CNKSR1, MAPK1, MAPK7 | MAPK14 10/4885CYP2C9 2849/4885MAPK13 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.